Assessing Capricor Therapeutics (CAPR) Valuation After Positive HOPE-3 Data and Nippon Shinyaku Commercialization Deal

Simply Wall St.
Dec 22, 2025

Capricor Therapeutics (CAPR) is back in focus after positive topline data from its Phase 3 HOPE-3 trial of Deramiocel for Duchenne muscular dystrophy, along with a new commercialization deal with ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10